Zhang GQ, Taylor JP, Stem M, et al. - Researchers examined colorectal cancer patients with metastasis to the liver, lung, or both sites for their demographic factors, treatment trends, and survival outcomes. The National Cancer Database (2010-2015) was explored for adults with a primary diagnosis of colorectal liver, lung, or liver and lung metastases. They included 82,609 adults; of these, 70.42% had liver, 8.74% lung, and 20.85% simultaneous liver and lung metastases. In these patients, the most utilized treatment was chemotherapy alone treatment (21.11%), followed by chemotherapy with colorectal radical resection (CRRR) (19.4%), no treatment (14.35%), CRRR alone (9.03%), and chemotherapy with CRRR and liver/lung resection (L/LR) (8.22%). Observations revealed a significantly better 5-year OS among patients with lung metastasis (15.99%, 16.70%, 5.51%) vs the other two metastatic groups even after stratifying by treatment type, adjusting for other factors. The greatest reduction in mortality risk for all sites was evident in correlation with chemotherapy with CRRR and L/LR while forgoing treatment or CRRR alone offered the worst OS.